Frankfurt - Delayed Quote EUR

Bioretec Oy (0TN.F)

2.1100

-0.0200

(-0.94%)

As of 3:29:02 PM GMT+2. Market Open.

Bioretec Ltd's Board of Directors has decided on a new option program for the CEO

The Board of Directors of Bioretec Ltd has on 21st of March 2025 resolved, on the basis of the authorization granted by the company's Annual General Meeting on 21st of March 2025, to establish a new option program as an incentive scheme for Alan Donze, the CEO of the company (the "CEO").

PR Newswire 21 days ago

BRETEC.HE
Resolutions of Bioretec Ltd´s Annual General Meeting and the constitutive meeting of the Board of Directors

The Annual General Meeting of Bioretec Ltd was held on 21 March 2025 in Tampere, Finland.

PR Newswire 21 days ago

BRETEC.HE
Bioretec Ltd: Notification in accordance with chapter 9, section 10 of the Securities Market Act on a change in holdings (W&M GmbH)

Bioretec Ltd has on 14 March 2025 received a notification in accordance with the Securities Market Act, according to which the holdings of shares and votes of W&M GmbH in Bioretec Ltd have on 14 March 2025 crossed the threshold of 5%.

PR Newswire 28 days ago

BRETEC.HE
Bioretec Ltd's Annual Report 2024 published

Bioretec Ltd has today published its 2024 Annual Report. The Annual Report is attached to this release and also available in Finnish and English on the company's website at https://investors.bioretec.com/en/reports_and_presentations. Bioretec's previously published financial statements for 2024 are also available on the company's website.

PR Newswire 28 days ago

BRETEC.HE
NOTICE OF ANNUAL GENERAL MEETING OF BIORETEC LTD

Bioretec Ltd Company announcement 28 February at 12.30 p.m. EET

PR Newswire last month

BRETEC.HE
CE Mark Approval for RemeOs™ Trauma Screw Product Group, featuring four product lines with over 200 individual products, drives global expansion for Bioretec

Bioretec Ltd., a pioneer in absorbable orthopedic implants, has achieved a pivotal milestone with the successful completion of its CE mark approval process for the RemeOs™ Trauma Screw product portfolio. With the CE mark, Bioretec can immediately start selling products in Europe through the distribution network used by the company's Activa products. The CE mark now obtained covers a wide range of indications for both adult and pediatric patients across the upper and lower extremities, enabling B

PR Newswire last month

BRETEC.HE
Bioretec Ltd's Financial Statements 2024 published

Bioretec Ltd has today published its 2024 Financial Statements and Report by the Board of Directors. The publications are attached to this release and also available in Finnish and English on the company's website at www.bioretec.com/investors/investors-in-english/reports-and-presentations.

PR Newswire last month

BRETEC.HE

0TN.DU

0TN.F
-0.94%
Bioretec Ltd's financial statements bulletin 2024: Foundation for future growth in 2024 - CE mark received in January 2025

Bioretec Ltd Company announcement 14 February 2025 at 8:00 a.m.

PR Newswire last month

BRETEC.HE
Inside information: Bioretec Ltd. receives CE mark approval for RemeOs™ Trauma Screw product portfolio, allowing market launch in Europe

Bioretec Ltd., a pioneer in absorbable orthopedic implants, has successfully completed its CE mark approval process and can start commercialization of its RemeOs™ Trauma Screw product portfolio within the European Union and non-European countries that recognize the CE mark market authorization. This comprehensive approval covers all cannulated and non-cannulated product designs*, with sizes ranging from diameters of 2.0mm to 4.0mm and lengths from 8mm to 50mm. Indications approved include the us

PR Newswire 2 months ago

BRETEC.HE
Proposals of the Shareholders' Nomination Board of Bioretec Ltd to the Annual General Meeting 2025

The Shareholders' Nomination Board of Bioretec Ltd ("Bioretec") has resolved to make the following proposals to the Annual General Meeting. The Annual General Meeting of Bioretec is scheduled to be held on March 21, 2025, and the company will publish the notice of the meeting separately.

PR Newswire 2 months ago

BRETEC.HE
Bioretec signed a new sales and distribution agreement to accelerate the commercialization of RemeOs™ Trauma Screw in the U.S. civilian hospital market

Bioretec Ltd, a pioneering company dedicated to advancing biodegradable orthopedic implants, is moving ahead with the next phase of the commercialization of its innovative RemeOs™ Trauma Products in the U.S. market. As a continuation to the previously signed logistics agreement with GlobalMed Logistix, Bioretec strengthens now its commercialization efforts by signing a new sales and distribution agreement with Tri-State Biologics (TSB), which is a distributor of medical and surgical products bas

PR Newswire 4 months ago

BRETEC.HE
The commercialization of Bioretec's RemeOs™ Trauma Screw in the U.S. proceeds with the signing of new logistics agreement

Bioretec Ltd, a pioneering company dedicated to advancing biodegradable orthopedic implants, is moving ahead with the next phase of commercializing its innovative RemeOs™ Trauma Products in the U.S. market. Bioretec strengthens its operational efforts by entering into a new logistics agreement with a partner providing customer support services for U.S. operations. This agreement with GlobalMed Logistix (GMLx), a leader in healthcare logistics, will enable the smooth import and distribution of im

PR Newswire 4 months ago

BRETEC.HE
Bioretec Ltd's business review January-September 2024: Launch of the RemeOs™ Trauma Screw in the U.S. is proceeding to the next phase, EU authorization in the final stage

This announcement summarizes Bioretec Ltd's business review for January-September 2024. The complete business review is attached to this release as a PDF file and available on the company's website at https://bioretec.com/investors/investors-in-english/releases.

PR Newswire 4 months ago

BRETEC.HE
Inside information: Bioretec updates its product development strategy by accelerating the product development of RemeOs™ Spinal Interbody Cage

Bioretec updates its product development strategy by accelerating the product development of the RemeOs™ Spinal Interbody Cage, an innovative medical device engineered from a multifunctional, MRI-compatible, absorbable hybrid composite based on the company's proprietary magnesium alloy.

PR Newswire 6 months ago

BRETEC.HE
Inside information: Bioretec updates its financial targets

Bioretec Ltd announced today, 4 October 2024, that Bioretec's board of directors had decided to update the company's product development strategy by accelerating the product development of the RemeOs™ Spinal Interbody Cage following the granting of Breakthrough Device Designation status by the US Food and Drug Administration on 14 March 2024.

PR Newswire 6 months ago

BRETEC.HE
Bioretec's Shareholders' Nomination Board appointed

The following persons have been appointed to Bioretec's Shareholders' Nomination Board: Kustaa Poutiainen, Chair and Founder of Stephen Industries Inc Oy as Chair and Karoliina Lindroos, Head of Responsible Investment of Ilmarinen Mutual Pension Insurance Company and Marko Berg, Deputy Investment Officer of University of Helsinki, as members. The Chairman of the Board of Bioretec acts as an expert to the Nomination Board.

PR Newswire 6 months ago

BRETEC.HE
Bioretec Ltd's half-year report January-June 2024: RemeOs™ trauma screw controlled launch in the U.S. yielded expected positive clinical results

This announcement is a summary of Bioretec Ltd's half-year report January-June 2024. The complete half-year report with tables is attached to this release as a pdf file and available at the company's web pages at https://bioretec.com/investors/investors-in-english/releases.

PR Newswire 7 months ago

BRETEC.HE
Inside Information: Update for Bioretec's RemeOs™ Trauma Screw European Marketing Authorization

Bioretec Ltd., a pioneer in bioresorbable orthopedic implants, announces that according to the information received from the Notified Body (Dekra), its European CE mark market authorization application for the RemeOs™ trauma screw has returned from the expert panel evaluation. Although the previously estimated timeline projected that the CE mark would be obtained by the end of Q2 2024, we now anticipate that it will be issued later beyond this timeline.

PR Newswire 9 months ago

BRETEC.HE
$Bioretec reports successful clinical outcomes from U.S. controlled launch of RemeOs™ trauma screw: fracture healing confirmed in 100% of surgical procedures$

Bioretec reports successful clinical outcomes from U.S. controlled launch of RemeOs™ trauma screw: fracture healing confirmed in 100% of surgical procedures

Bioretec Ltd., a pioneer in biodegradable orthopedic implants, is pleased to announce that a number of cases have been performed around the U.S. utilizing the RemeOs™ technology. The follow-up results confirmed successful implantation and fracture healing were achieved in all cases. Surgeons reported very positive feedback in that there is no change to existing surgical technique while operating with an absorbable metal implant for their patients. The added benefit of osteopromotion and bioactiv

PR Newswire 9 months ago

BRETEC.HE
Inside information: Alan Donze has been appointed as Bioretec's new CEO

Bioretec Ltd is pleased to announce that Mr. Alan Donze has been appointed CEO of Bioretec as of today, 20 May 2024. He will start in this position immediately. With a distinguished career spanning the banking and medical device industries, Mr. Donze brings a wealth of experience and expertise to the Bioretec organization.

PR Newswire 10 months ago

BRETEC.HE

Performance Overview

Return	0TN.F	OMX Helsinki_PI (^OMXHPI)
YTD	-5.80%	0.00%
1-Year	-24.91%	0.00%
3-Year	-0.47%	0.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Bioretec Oy (0TN.F)

Bioretec Ltd's Board of Directors has decided on a new option program for the CEO

Resolutions of Bioretec Ltd´s Annual General Meeting and the constitutive meeting of the Board of Directors

Bioretec Ltd: Notification in accordance with chapter 9, section 10 of the Securities Market Act on a change in holdings (W&M GmbH)

Bioretec Ltd's Annual Report 2024 published

NOTICE OF ANNUAL GENERAL MEETING OF BIORETEC LTD

CE Mark Approval for RemeOs™ Trauma Screw Product Group, featuring four product lines with over 200 individual products, drives global expansion for Bioretec

Bioretec Ltd's Financial Statements 2024 published

Bioretec Ltd's financial statements bulletin 2024: Foundation for future growth in 2024 - CE mark received in January 2025

Inside information: Bioretec Ltd. receives CE mark approval for RemeOs™ Trauma Screw product portfolio, allowing market launch in Europe

Proposals of the Shareholders' Nomination Board of Bioretec Ltd to the Annual General Meeting 2025

Bioretec signed a new sales and distribution agreement to accelerate the commercialization of RemeOs™ Trauma Screw in the U.S. civilian hospital market

The commercialization of Bioretec's RemeOs™ Trauma Screw in the U.S. proceeds with the signing of new logistics agreement

Bioretec Ltd's business review January-September 2024: Launch of the RemeOs™ Trauma Screw in the U.S. is proceeding to the next phase, EU authorization in the final stage

Inside information: Bioretec updates its product development strategy by accelerating the product development of RemeOs™ Spinal Interbody Cage

Inside information: Bioretec updates its financial targets

Bioretec's Shareholders' Nomination Board appointed

Bioretec Ltd's half-year report January-June 2024: RemeOs™ trauma screw controlled launch in the U.S. yielded expected positive clinical results

Inside Information: Update for Bioretec's RemeOs™ Trauma Screw European Marketing Authorization

Bioretec reports successful clinical outcomes from U.S. controlled launch of RemeOs™ trauma screw: fracture healing confirmed in 100% of surgical procedures

Inside information: Alan Donze has been appointed as Bioretec's new CEO

Performance Overview